// App-Quantinova.ai

5050 : Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer Pharmacokinetics data from the PROpel trial.

Researchers

Presenter

  • Andrew J. Armstrong

Principal Investigators

  • Antoine Thiery-Vuillemin

  • Mototsugu Oya

  • Giuseppe Procopio

  • Juliana Janoski De Menezes

  • Gustavo Colagiovanni Girotto

  • Pooja Ghatalia

  • Franco Nole

  • Omar Din

  • Philipp Spiegelhalder

  • Ivan Mincik

  • Robbert J. van Alphen

  • Nicolaas Lumen

  • Christian Hosius

  • Diansong Zhou

  • Laura Barker

  • Melanie Elizabeth Dujka

  • Fred Saad

Medical Centers

  • Duke University Medical Center, Durham, NC

  • The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom

  • CHRU Besançon Hôpital J.Minjoz, Besançon, France

  • Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan

  • Istituto Nazionale Tumori, Milano, Italy

  • Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil

  • Hospital de Base de Sao Jose do Rio Preto, Sao Jose Do Rio Preto/SP, Brazil

  • Fox Chase Cancer Center, Philadelphia, PA

  • Medical Oncology Division of Urogenital and Head and Neck Tumors, European Institute of Oncology, Milan, Italy

  • Weston Park Cancer Centre, Sheffield, United Kingdom

  • Urologie Neandertal, Mettmann, Germany

  • Urocentrum Milab, Presov, Slovakia

  • Department of Internal Medicine, Elisabeth-Tweesteden Hospital, Tilburg, Netherlands

  • Department of Radiation Oncology, Ghent University Hospital, Gent, Belgium

  • Merck Sharp & Dohme GmbH, Munich, Germany

  • AstraZeneca, Waltham, MA

  • Astra Zeneca, Cambridge, United Kingdom

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

Locations

  • United States

  • United Kingdom

  • France

  • Japan

  • Italy

  • Brazil

  • Germany

  • Slovakia

  • Netherlands

  • Belgium

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Prednisolone

  • CB-7598

  • Prednisone

  • Olaparib

  • Propel

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

Phase

  • III

Study Id's

  • NCT03732820

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved